Mobia Medical (MOBI): First Take: Two Year VNS Data Supports Longer-Term Efficacy

Research evidence excerpt

Mobia Medical (MOBI): First Take: Two Year VNS Data Supports Longer-Term Efficacy

Equity Research

14 July 2026 | 4:36PM PDT

Mobia Medical (MOBI): First Take: Two Year VNS Data Supports

Longer-Term Efficacy

On Tuesday, July 14th, Mobia Medical announced the publication of two-year David Roman

+1(212)357-4617 |

follow-up data from its VNS-REHAB clinical trial. The trial reaffirmed clinical efficacy david.roman@gs.com

Goldman Sachs & Co. LLC

of VNS therapy and expanded on the available pivotal trial data (prior one-year) with

Jamie Perse, CFA

now a two-year follow period. +1(212)902-8192 | jamie.perse@gs.com

Shares of MOBI have been volatile since its IPO price (-23% since IPO price vs. the Philip Coover

Russell 2000 +4%), which we think mostly reflects broader MedTech volatility. We +1(917)343-8573philip.coover@gs.com|

view today’s positive data as adding confidence to the longer term Vivistim Goldman Sachs & Co. LLC

Jenny Rabinowitzopportunity and reiterate our Buy rating. When it comes to the catalyst path for +1(212)855-0819 |

the stock, we look to the following for further evidence on our positive view, most jenny.rabinowitz@gs.comGoldman Sachs & Co. LLC

notable: updates on commercial execution with 2Q26 earnings likely in August and Marco Espaillat

further clinical data (with several upcoming medical meetings — Society of +1(212)902-6790 | marco.espaillat@gs.com

NeuroInterventional Surgery in July and the Congress of Neurological Surgeons in Goldman Sachs & Co. LLC

October).

The basis of our constructive outlook sits on the wide unmet need of stroke patients

within the U.S. Following the company’s recent IPO, we continue to believe that

Vivistim Paired VNS Therapy represents a paradigm-shifting technology in the stroke

rehabilitation market.